Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.
NN9490-7611
Phase 1 other active
Quick answer
Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function. for Obesity and Diabetes mellitus Typ 2 is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Obesity and Diabetes mellitus Typ 2
- Phase
- Phase 1
- Modality
- other
- Status
- active